- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00907153
Vitamin D for the Treatment of Women With Polycystic Ovary Syndrome (PCOS)
Vitamin D Supplementation in Polycystic Ovary Syndrome: a Randomized Controlled Trial.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
As many cells throughout the body possess the vitamin D receptor, adequate vitamin D levels may be essential for multiple physiologic functions. In recent years, vitamin D insufficiency has been linked to insulin resistance, inflammation, poor psychological health, obesity, type 2 diabetes, and cardiovascular disease - these are also commonly found in women with Polycystic Ovary syndrome (PCOS). We believe that vitamin D insufficiency contributes to insulin resistance, inflammation, and psychological distress in women with PCOS. These adverse effects may ultimately increase the risk for serious long-term complications in PCOS, including type 2 diabetes and cardiovascular disease. The key objectives of this research study are to determine the effects of vitamin D supplementation on insulin resistance, inflammation, mood and overall well-being in women with PCOS.
The protocol has been modified by adding the following specific aim: To compare vascular function in healthy age and BMI similar matched women to PCOS women pre-treatment. Our hypothesis is that PCOS women will have greater attenuations in retinal vascular reactivity compared to healthy control women, demonstrating poorer endothelial function. We are currently recruiting healthy women who are age and BMI similar to the PCOS women and measure their retinal vascular reactivity for comparisons to the PCOS women's pre-treatment vascular reactivity. These healthy women will only have a baseline visit in which retinal vascular reactivity will be measured. They will not be enrolled in the placebo or Vitamin D randomization process as described above.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Pennsylvania
-
Hershey, Pennsylvania, Vereinigte Staaten, 17033
- Penn State College of Medicine, Penn State Milton S Hershey Medical Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
Diagnosis of PCOS based on:
- Eight or fewer menstrual periods per year or spontaneous intermenstrual periods of greater than or equal to 45 days, and
- Elevated testosterone levels
Exclusion Criteria:
- Current Pregnancy or Nursing
- Elevated calcium
- Kidney Stones or kidney disease
- Current use of vitamin D (other than a multivitamin)
- Use of metformin or other insulin sensitizing drugs in the last 3 months
- Elevated prolactin or untreated thyroid disease
- Diabetes, Liver disease, Heart disease, or other serious medical condition
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Placebo-Komparator: Placebo
|
Placebo by mouth once daily for 12 weeks
|
Experimental: Vitamin-D
|
Vitamin D 300 mcg by mouth once daily for 12 weeks
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Change From Baseline in Mean Quantitative Insulin Sensitivity Check Index (QUICKI)
Zeitfenster: Baseline and 12 weeks
|
Quantitative insulin sensitivity check index (QUICKI) is a validated measure of insulin sensitivity based on fasting insulin and glucose.
Quantitative insulin sensitivity check index (QUICKI) = 1/[log(I(0)) + log(G(0))]).
|
Baseline and 12 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Change From Baseline in Mean High Sensitive C-reactive Protein (hsCRP)
Zeitfenster: Baseline and 12 weeks
|
High sensitive C-reactive protein (hsCRP) was assessed as a measure of inflammation.
|
Baseline and 12 weeks
|
Change From Baseline in Mean Systolic Blood Pressure
Zeitfenster: Baseline and 12 weeks
|
Blood pressure was measured in the right arm in the sitting position after a 15-minute rest.
|
Baseline and 12 weeks
|
Change From Baseline in Mean Diastolic Blood Pressure
Zeitfenster: Baseline and 12 weeks
|
Blood pressure was measured in the right arm in the sitting position after a 15-minute rest.
|
Baseline and 12 weeks
|
Change From Baseline in Mean Fasting Glucose
Zeitfenster: Baseline and 12 weeks
|
Glucose was assessed after 12 hours of fasting.
|
Baseline and 12 weeks
|
Change From Baseline in Mean Fasting Insulin
Zeitfenster: Baseline and 12 weeks
|
Insulin was assessed after 12 hours of fasting.
|
Baseline and 12 weeks
|
Change From Baseline in Mean 2-hour Glucose
Zeitfenster: Baseline and 12 weeks
|
Participants underwent a 75-gram oral glucose tolerance test, in which blood samples for glucose and insulin were obtained at 0 and 2 hours and used to calculate the insulin sensitivity index (ISI 0,120).
|
Baseline and 12 weeks
|
Change From Baseline in Mean 2-hour Insulin
Zeitfenster: Baseline and 12 weeks
|
Participants underwent a 75-gram oral glucose tolerance test, in which blood samples for glucose and insulin were obtained at 0 and 2 hours and used to calculate the insulin sensitivity index (ISI 0,120).
|
Baseline and 12 weeks
|
Change From Baseline in Mean Insulin Sensitivity Index (ISI 0,120)
Zeitfenster: Baseline and 12 weeks
|
Participants underwent a 75-g oral glucose tolerance test, in which blood samples for glucose and insulin were obtained at 0 and 120 minutes and used to calculate the insulin sensitivity index (ISI0,120).
The ISI 0,120 = the glucose uptake rate divided by the mean plasma glucose divided by the log(mean serum insulin).
|
Baseline and 12 weeks
|
Change From Baseline in Mean Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
Zeitfenster: Baseline and 12 weeks
|
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) is a validated measure of insulin resistance based on fasting insulin and glucose.
HOMA-IR is calculated as the product of fasting glucose and insulin divided by 22.5.
|
Baseline and 12 weeks
|
Change From Baseline in Mean Total Cholesterol
Zeitfenster: Baseline and 12 weeks
|
Lipid profile was assessed after 12 hours of fasting.
|
Baseline and 12 weeks
|
Change From Baseline in Mean HDL Cholesterol
Zeitfenster: Baseline and 12 weeks
|
Lipid profile was assessed after 12 hours of fasting.
|
Baseline and 12 weeks
|
Change From Baseline in Mean LDL Cholesterol
Zeitfenster: Baseline and 12 weeks
|
Lipid profile was assessed after 12 hours of fasting.
|
Baseline and 12 weeks
|
Change From Baseline in Mean Triglycerides
Zeitfenster: Baseline and 12 weeks
|
Lipid profile was assessed after 12 hours of fasting.
|
Baseline and 12 weeks
|
Change From Baseline in Mean Total Testosterone
Zeitfenster: Baseline and 12 weeks
|
Total and free testosterone levels were assessed from blood samples to evaluate effects on hyperandrogenemia in PCOS.
|
Baseline and 12 weeks
|
Change From Baseline in Mean Free Testosterone
Zeitfenster: Baseline and 12 weeks
|
Total and free testosterone levels were assessed from blood samples to evaluate effects on hyperandrogenemia in PCOS.
|
Baseline and 12 weeks
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Change From Baseline in Mean 25-hydroxyvitamin D
Zeitfenster: Baseline and 12 weeks
|
Total 25-hydroxyvitamin D was assayed by the Immunodiagnostic Systems radioimmunoassay.
|
Baseline and 12 weeks
|
Change From Baseline in Mean Vitamin D Binding Protein
Zeitfenster: Baseline and 12 weeks
|
Vitamin D binding protein levels were assessed as it has been linked with insulin resistance and type 2 diabetes.
|
Baseline and 12 weeks
|
Change From Baseline in Mean Intact Parathyroid Hormone (i-PTH)
Zeitfenster: Baseline and 12 weeks
|
Intact parathyroid hormone levels were assessed as they have been linked with obesity and insulin resistance.
|
Baseline and 12 weeks
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Nazia Raja-Khan, M.D., Penn State College of Medicine, Penn State Milton S. Hershey Medical Center
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 29714
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur PCO-Syndrom
-
Riphah International UniversityAbgeschlossen
-
Riphah International UniversityAbgeschlossen
-
Shaare Zedek Medical CenterUnbekanntPrämenstruelles Syndrom-PMS
-
Esra ÖZERKTO Karatay UniversityRekrutierungPrämenstruelles Syndrom-PMSTruthahn
-
Assistance Publique - Hôpitaux de ParisRekrutierungIntensivstation-Syndrom | Pädiatrisches Post-Intensivpflege-SyndromFrankreich
-
University of CalgaryUnbekanntNephrotisches Syndrom bei Kindern | Nephrotisches Syndrom, minimale Veränderung | Nephrotisches Syndrom, idiopathischKanada
-
King Saud UniversityUnbekanntImpingement-Syndrom, SchulterSaudi-Arabien
-
Riphah International UniversityRekrutierungUpper-Cross-SyndromPakistan
-
Cairo UniversityNoch keine Rekrutierung
-
Cairo UniversityRekrutierung
Klinische Studien zur Vitamin D
-
Khon Kaen UniversityNoch keine Rekrutierung
-
Fundación Cardiovascular de ColombiaUniversidad Industrial de Santander; Farma de Colombia SAAbgeschlossenMangel an Vitamin D | Übergewicht und Adipositas | Übergewichtige JugendlicheKolumbien
-
Nutrition Institute, SloveniaSlovenian Research Agency; Higher School of Applied Sciences (VIST); Valens Int...AbgeschlossenMangel an Vitamin DSlowenien
-
USDA, Western Human Nutrition Research CenterAbgeschlossenMangel an Vitamin DVereinigte Staaten
-
Fundación Pública Andaluza para la gestión de la...AbgeschlossenTransplantation hämatopoetischer StammzellenSpanien
-
University Hospital, Basel, SwitzerlandAbgeschlossenMangel an Vitamin DSchweiz
-
University of ViennaUnbekannt
-
University of AarhusNoch keine RekrutierungErkrankungen des Immunsystems | Wachstum | Entwicklung des Kindes | Vitamin-D-Ergänzung
-
Pauls Stradins Clinical University HospitalAbgeschlossen
-
Andrea BranchUnbekanntHepatozelluläres Karzinom | Mangel an Vitamin DVereinigte Staaten